ASND - Ascendis Pharma A/S

QQQ $ 431.66 $ -1.49 (-0.34 %)

DIA $ 383.22 $ 0.09 (0.02 %)

SPY $ 509.52 $ -0.74 (-0.15 %)

TLT $ 88.55 $ -0.14 (-0.16 %)

GLD $ 215.81 $ -0.29 (-0.13 %)

Previous Close

$ 135.9

Open

$ 138.00

Bid

$ 0.00 x 0

Ask

$ 0.00 x 0

Day's Range

$ 133.76 - $ 138.00

52 Week Range

$ 66.03 - $ 161.00

Volume

226,133

Average Volume

Market Cap

7.84B

Beta (5Y Monthly)

$ 0.71

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type	Report Link
No Data found

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

looking-into-ascendis-pharmas-recent-short-interest

Looking Into Ascendis Pharma's Recent Shor...
04/26/2024 15:30:29

MHRA Approves YORVIPATH In Great Britain F...
04/24/2024 12:31:30

Morgan Stanley Maintains Equal-Weight on A...
04/22/2024 17:15:47

Morgan Stanley analyst Vikram Purohit maintains Ascendis Pharma (NASDAQ:ASND) with a Equal-Weight and maintains $116 price t...

1000-invested-in-ascendis-pharma-15-years-ago-would-be-worth-this-much-today

$1000 Invested In Ascendis Pharma 15 Years...
04/18/2024 19:30:33

Cantor Fitzgerald Reiterates Overweight on...
04/18/2024 13:43:37

Cantor Fitzgerald analyst Li Watsek reiterates Ascendis Pharma (NASDAQ:ASND) with a Overweight and maintains $173 price target.

heres-how-much-you-would-have-made-owning-ascendis-pharma-stock-in-the-last-10-years

Here's How Much You Would Have Made Owning...
04/03/2024 17:00:31

JP Morgan Maintains Overweight on Ascendis...
04/02/2024 14:47:36

JP Morgan analyst Jessica Fye maintains Ascendis Pharma (NASDAQ:ASND) with a Overweight and raises the price target from $16...

Cantor Fitzgerald Reiterates Overweight on...
04/01/2024 12:35:23

Cantor Fitzgerald analyst Li Watsek reiterates Ascendis Pharma (NASDAQ:ASND) with a Overweight and maintains $173 price target.

Wells Fargo Maintains Overweight on Ascend...
03/15/2024 12:41:40

Wells Fargo analyst Derek Archila maintains Ascendis Pharma (NASDAQ:ASND) with a Overweight and raises the price target from...

heres-how-much-100-invested-in-ascendis-pharma-15-years-ago-would-be-worth-today

Here's How Much $100 Invested In Ascendis ...
03/14/2024 14:00:15

these-five-small-cap-stocks-under-the-radar-are-expected-to-surge-says-stock-researcher

These Five Small-Cap Stocks Under The Rada...
03/03/2024 19:57:14

Ethan Meyers, the research director at Westfield Capital Management, has a knack for identifying promising investments that hav...

1000-invested-in-this-stock-15-years-ago-would-be-worth-45000-today

$1000 Invested In This Stock 15 Years Ago ...
02/23/2024 16:00:25

how-is-the-market-feeling-about-ascendis-pharma

How Is The Market Feeling About Ascendis P...
02/13/2024 13:15:18

if-you-invested-1000-in-this-stock-10-years-ago-you-would-have-70000-today

If You Invested $1000 In This Stock 10 Yea...
02/08/2024 16:30:29

Citigroup Maintains Buy on Ascendis Pharma...
02/08/2024 16:07:37

Citigroup analyst David Lebowitz maintains Ascendis Pharma (NASDAQ:ASND) with a Buy and raises the price target from $146 to...

Wedbush Maintains Outperform on Ascendis P...
02/08/2024 13:27:42

Wedbush analyst Andreas Argyrides maintains Ascendis Pharma (NASDAQ:ASND) with a Outperform and raises the price target from...

Ascendis Pharma Q4 2023 GAAP EPS $(1.66) M...
02/07/2024 22:02:02

Ascendis Pharma (NASDAQ:ASND) reported quarterly losses of $(1.66) per share which missed the analyst consensus estimate of $(1...

Earnings Scheduled For February 7, 2024
02/07/2024 10:13:28

Companies Reporting Before The Bell • Madison Square Garden (NYSE:MSGE) is expected to report quarterly loss at $0.80 per shar...

Ascendis Pharma's Earnings: A Preview
02/06/2024 17:01:16

Cantor Fitzgerald Maintains Overweight on ...
02/06/2024 14:49:32

Cantor Fitzgerald analyst Li Watsek maintains Ascendis Pharma (NASDAQ:ASND) with a Overweight and raises the price target fr...